NYSE:QGEN

Stock Analysis Report

Executive Summary

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide.


Snowflake Analysis

Moderate growth potential and overvalued.


Similar Companies

Share Price & News

How has QIAGEN's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QGEN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

11.1%

QGEN

5.6%

US Life Sciences

10.5%

US Market


1 Year Return

-0.6%

QGEN

-7.1%

US Life Sciences

-11.5%

US Market

Return vs Industry: QGEN exceeded the US Life Sciences industry which returned -7.1% over the past year.

Return vs Market: QGEN exceeded the US Market which returned -11.5% over the past year.


Shareholder returns

QGENIndustryMarket
7 Day11.1%5.6%10.5%
30 Day10.9%-9.5%-15.4%
90 Day20.1%-17.8%-21.4%
1 Year-0.6%-0.6%-7.0%-7.1%-9.6%-11.5%
3 Year39.6%39.6%58.1%57.1%12.6%5.4%
5 Year60.8%54.7%83.2%80.7%32.8%18.1%

Price Volatility Vs. Market

How volatile is QIAGEN's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is QIAGEN undervalued compared to its fair value and its price relative to the market?

3.63x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: QGEN ($40.45) is trading above our estimate of fair value ($31.45)

Significantly Below Fair Value: QGEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: QGEN is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: QGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QGEN is good value based on its PB Ratio (3.6x) compared to the US Life Sciences industry average (4.2x).


Next Steps

Future Growth

How is QIAGEN forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

34.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: QGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: QGEN's is expected to become profitable in the next 3 years.

Revenue vs Market: QGEN's revenue (5.4% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: QGEN's revenue (5.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (12%).


Next Steps

Past Performance

How has QIAGEN performed over the past 5 years?

-9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QGEN is currently unprofitable.

Growing Profit Margin: QGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QGEN is unprofitable, and losses have increased over the past 5 years at a rate of -9% per year.

Accelerating Growth: Unable to compare QGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QGEN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (25.8%).


Return on Equity

High ROE: QGEN has a negative Return on Equity (-1.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is QIAGEN's financial position?


Financial Position Analysis

Short Term Liabilities: QGEN's short term assets ($1.6B) exceed its short term liabilities ($951.3M).

Long Term Liabilities: QGEN's short term assets ($1.6B) do not cover its long term liabilities ($1.7B).


Debt to Equity History and Analysis

Debt Level: QGEN's debt to equity ratio (67.5%) is considered high.

Reducing Debt: QGEN's debt to equity ratio has increased from 43.8% to 67.5% over the past 5 years.


Balance Sheet

Inventory Level: QGEN has a low level of unsold assets or inventory.

Debt Coverage by Assets: QGEN's debt is not covered by short term assets (assets are 0.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QGEN has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: QGEN has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is QIAGEN's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Thierry Bernard (54yo)

0.42

Tenure

US$1,307,869

Compensation

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020. He served as Interim Chief Executive Officer of Qiagen NV since October 2019 until March 2020. He has been a Senior Vic ...


CEO Compensation Analysis

Compensation vs Market: Thierry's total compensation ($USD1.31M) is below average for companies of similar size in the US market ($USD7.47M).

Compensation vs Earnings: Insufficient data to compare Thierry's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Thierry Bernard
Chief Executive Officer0.42yrUS$1.31m0.021% $1.9m
Roland Sackers
CFO, MD & Member of Management Board16.17yrsUS$1.07m0.082% $7.6m
Peer Schatz
Senior Advisor0.42yrUS$7.98m1.29% $120.0m
Barthold Piening
Senior VP & Head of Global Operations1.25yrsno datano data
John Gilardi
Vice President of Corporate Communications & Investor Relations9.42yrsno datano data
Jean-Pascal Viola
Head of Corporate Business Development4.83yrsno datano data
Stephany Foster
SVP & Head of Human Resources0.42yrno datano data
Thomas Schweins
Senior Vice President of Life Science Business Area2.17yrsno datano data
Jonathan Sheldon
Senior Vice President of Qiagen Digital Insights Business Area2.17yrsno datano data
Thomas Neidert
Vice President of Global Treasuryno datano datano data

2.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: QGEN's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Metin Colpan
Independent Supervisory Director16.17yrsUS$75.50k1.56% $145.1m
Elizabeth Tallett
Independent Supervisory Director8.75yrsUS$96.50k0.013% $1.2m
Sven Björklund
Independent Supervisory Board Chairman1.75yrsUS$173.00kno data
Lawrence Rosen
Independent Supervisory Director6.75yrsUS$82.50kno data
Elaine Mardis
Independent Supervisory Director5.75yrsUS$63.50k0.0026% $243.4k
Stéphane Bancel
Independent Supervisory Director6.75yrsUS$89.50k0.0070% $650.3k

6.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: QGEN's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: QGEN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

QIAGEN N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: QIAGEN N.V.
  • Ticker: QGEN
  • Exchange: NYSE
  • Founded: 1986
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$9.289b
  • Shares outstanding: 227.63m
  • Website: https://www.qiagen.com

Number of Employees


Location

  • QIAGEN N.V.
  • Hulsterweg 82
  • Venlo
  • Limburg
  • 5912 PL
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QGENNYSE (New York Stock Exchange)YesCommon SharesUSUSDJun 1996
QIADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 1996
QIAXTRA (XETRA Trading Platform)YesCommon SharesDEEURJun 1996
0RLTLSE (London Stock Exchange)YesCommon SharesGBEURJun 1996
QIADBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJun 1996
QGENSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJun 1996
QGENWBAG (Wiener Boerse AG)YesCommon SharesATEURJun 1996
QIAETLX (Eurotlx)YesCommon SharesITEURJun 1996

Biography

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels (DNA and RNA), library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc., CLIA-certified laboratories, and NuProbe Global. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 02:36
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.